<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361630</url>
  </required_header>
  <id_info>
    <org_study_id>SVSIDS/PERIO/3/2018</org_study_id>
    <nct_id>NCT04361630</nct_id>
  </id_info>
  <brief_title>Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Gingival Recession Defects</brief_title>
  <official_title>Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Absorbable Collagen Membrane With Coronally Advanced Flap In Class I And II Gingival Recession Defects -A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SVS Institute of Dental Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SVS Institute of Dental Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a single-arm trial to obtain preliminary data on the efficacy of collagen
      membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the
      treatment of Miller's class I and class II gingival recessions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Soft tissues can be regenerated to cover root exposure and a thin biotype can be converted
      into a thick biotype by using recombinant human growth factor technology. A recent review
      stated that growth factors could enhance soft tissue regeneration which includes restoration
      of mucogingival architecture and regeneration of periodontal hard and soft tissues including
      bone, cementum and periodontal ligament fibers. Fibroblast growth factor-2 (FGF-2), a
      heparin-binding cytokine with strong angiogenic activity stimulates the proliferation of
      undifferentiated mesenchymal cells. These functions can be applied in mucogingival surgery as
      FGF-2 promotes bone and cementum formation and exhibits an increased potential to promote
      periodontal regeneration in recession defects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the treatment of Miller's class I and class II gingival recessions.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Single Blinded trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Width of keratinized gingiva (wKG)</measure>
    <time_frame>5 months</time_frame>
    <description>To assess the wKG, the mucogingival junction was identified visually as the border between the movable (alveolar mucosa) and immovable tissue (gingiva). The distance from the gingival margin to the mucogingival junction was considered as the Wkg.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Main treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collagen membranes incorporating 10ng/ml human recombinant basic fibroblast growth factor (FGF-2/bFGF) will be placed in the sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FGF 2</intervention_name>
    <description>Following a standard surgical protocol, rhFGF-2 impregnated membranes will be placed in sites with gingival recession.</description>
    <arm_group_label>Main treatment group</arm_group_label>
    <other_name>FGF+Collagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  systemically healthy subjects between 20-55 years presenting with Miller's class I or
             class II gingival recession[

        Exclusion Criteria:

          -  1. Recessions associated with root demineralization/caries, deep cervical abrasion or
             pulpal pathology, 2. Patients with history of systemic conditions affecting
             periodontium and, 3. Smokers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>SVS Institute of Dental Sciences, Mahabubnagar</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>509002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SVS Institute of Dental Sciences</investigator_affiliation>
    <investigator_full_name>Dr R Viswa Chandra</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Gingival Recession</keyword>
  <keyword>Fibroblast Growth Factor 2</keyword>
  <keyword>Periodontal Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Gingival Recession</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No current plans to share data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

